# A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Source: https://onco.cc/trials/nct05304377/  
OnCo record `nct05304377` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Relcobatinib run by Enliven Therapeutics, now recruiting.

## Summary

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia is a phase 1 interventional study registered as NCT05304377 by Enliven Therapeutics, with 250 participants planned, started 2022-05-22. Conditions recorded: Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive and Cml. Interventions recorded: ELVN-001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05304377
- Phase: 1
- Setting: A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia
- Sponsor: Enliven Therapeutics
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT05304377: https://clinicaltrials.gov/study/NCT05304377

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Relcobatinib](https://onco.cc/drugs/relcobatinib/)
- companies: [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05304377.json